system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, METHODS, METHODS, METHODS, METHODS, RESULTS. Meshes: Calcium, Dietary, Female, Humans, Kidney Failure, Chronic, Magnesium, Male, Middle Aged, Phosphates, Phosphorus, Phosphorus Metabolism Disorders, Prospective Studies, Renal Dialysis, Treatment Outcome.
user
Is magnesium carbonate an effective phosphate binder for chronic hemodialysis patients : a pilot study? Context: This study was designed to evaluate the efficacy of magnesium carbonate as a phosphate binder in hemodialysis patients. This study was a prospective, randomized, open-label trial comparing magnesium carbonate/calcium carbonate versus calcium acetate as a sole phosphate binder. This study involved outpatient hemodialysis. We recruited 30 stable hemodialysis patients without a history of frequent diarrhea. After receiving informed consent, we randomized patients 2:1 to magnesium carbonate versus calcium acetate. The dose of each binder was titrated to achieve the Kidney Disease Outcomes Quality Initiative (K/DOQI) phosphate target of <5.5 mg/dL. The efficacy-phase serum phosphorus concentration and the percentage of patients meeting K-DOQI targets for phosphorus, along with the daily elemental calcium intake, were the primary outcome measures. Magnesium carbonate provided equal control of serum phosphorus (70.6% of the magnebind group and 62.5% of the calcium acetate group had their average serum phosphorus within the K-DOQI target during the efficacy phase), while significantly reducing daily elemental calcium ingestion from phosphate binders (908 +/- 24 vs. 1743 +/- 37 mg/day, P < .0001).
assistant
Magnesium carbonate was generally well-tolerated in this selected patient population, and was effective in controlling serum phosphorus while reducing elemental calcium ingestion. Final Decision: yes